Die Möglichkeiten eines supportiven Einsatzes der Phytotherapie bei Brustkrebspatientinnen^[*]

Zusammenfassung

Chemo- und Hormontherapie des Mammakarzinoms gehen häufig mit unerwünschten Wirkungen einher, die für die betroffenen Patientinnen derart belastend sein können, dass ein Fortsetzen der geplanten Therapie bisweilen unmöglich ist. Ziel dieser Arbeit ist es, anhand einer Literaturrecherche am Beispiel der 3 hierzu am besten untersuchten Pflanzen Gelbwurz (Curcuma longa), Mariendistel (Silybum marianum) und Traubensilberkerze (Cimicifuga racemosa) eine mögliche Bedeutsamkeit der Phytotherapie in der supportiven Behandlung v. a. durch Linderung dieser Beschwerden zu untersuchen. Im Vordergrund stehen die Ergebnisse klinischer Studien. Studien zur Misteltherapie in vergleichbaren klinischen Situationen wurden dabei wegen leicht erreichbarer Übersichtsarbeiten bewusst nicht bearbeitet.

Für alle 3 untersuchten Pflanzen fanden sich in den wenigen publizierten klinischen Studien positive Trends, die eine supportive Anwendung bei Brustkrebspatientinnen unter Chemo- und Hormontherapie nahelegen. Es wäre wünschenswert, wenn dieser Trend sich durch weitere qualitativ hochwertige Studien bestätigen ließe.

Summary

The potential role of phytotherapy as a supportive treatment in breast cancer patients Chemotherapy and endocrine therapy of breast cancer are often accompanied by undesirable side effects, which can be so debilitating for the patient, that continuation of the treatment might not be possible. Based on a literature review of clinical trials on three plants, turmeric (Curcuma longa), milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa), the objective of this article is to investigate a potential role of phytotherapy as a supportive treatment of some of the side effects encountered by breast cancer patients undergoing chemo- or endocrine therapy. This article deliberately did not include studies on mistletoe therapy in comparable clinical situations due to the ready availability of a wide range of appropriate reviews.

The few published clinical trials on all three plants show a positive trend with regards to their potential as a supportive treatment of breast cancer patients. However, more high-quality trials are required to corroborate the findings in this review.

Schlüsselwörter

Phytotherapie - Brustkrebs - unerwünschte Wirkungen - Curcuma longa - Silybum marianum - Cimicifuga racemosa

Key words

phytotherapy - breast cancer - side effects - Curcuma longa - Silybum marianum - Cimicifuga racemosa

^* Die hier veröffentliche Arbeit ist eine Abschluss­arbeit aus der Fortbildungsreihe „Phytotherapie für Ärzte“ in der Klinik Blankenstein, Hattingen 2014–2016. Prof. Dr. med. André-Michael Beer begleitete fachlich die Manuskriptentstehung.

• Literatur

• 1 Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009; 30: 85-94
• 2 Beer AM. Neff A. Differentiated evaluation of extract-specific evidence on Cimicifuga race­mosa’s efficacy and safety for climacteric complaints. Evid Based Complement Alternat Med 2013; 2013: 860602
• 3 Belcaro G, Hosoi M, Pellegrini L. et al. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytother Res 2014; 28: 444-450
• 4 Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat 2002; 76: 1-10
• 5 Boh M, Breakspear I. Herbal Monograph: Silybum marianum – ancient medicine for modern times. http://www.anpa.asn.au (Accessed: 14 April 2015)
• 6 Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of Sylimarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 2007; 6: 120-129
• 7 Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004; 3: 294-300
• 8 Enjalbert F, Rapior S, Nougier-Soulé J. et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002; 40: 715-757
• 9 Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009; 6: 928-939
• 10 Goel A, Aggarwal BB.. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010; 62: 919-930
• 11 Green J, Kalisch A, the CAM-Cancer Consortium. Milk thistle (Silybum marianum). http://www.cam-cancer.org/CAM-Summaries/ Herbal-products/Milk-thistle-Silybum-marianum; 2013 (Accessed: 14 April 2015)
• 12 Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applications of Silybum marianum in oncology. Integr Cancer Ther 2007; 6: 158-165
• 13 Henneicke-von Zepelin HH, Meden H, Kostev K. et al. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J. Clin Pharmacol Ther 2007; 45: 143-154
• 14 Invernizzi R, Bernuzzi S, Ciani D, Ascari E. Silymarine during maintenance therapy of acute promyelocytic leukemia. Haematologica 1993; 78: 340-341
• 15 Jacobson JS, Troxel AB, Evans J. et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001; 19: 2739-2745
• 16 Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-153
• 17 Ladas EJ, Kelly KM. Milk thistle: Is there a role for its use as an adjunct therapy in patients with cancer?. J Altern Complement Med 2003; 9: 411-416
• 18 Ladas EJ, Kroll DJ, Oberlies NH. et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 2010; 116: 506-513
• 19 McBride A, Augustin KM, Nobbe J, Westervelt P. Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia. J Oncol Pharm Practice 2012; 18: 360-365
• 20 Muñoz GH, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003; 44 (Suppl. 01) S59-S65
• 21 Naser B, Schnitker J, Minkin MJ. et al. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled trials for isopropanolic black cohosh extract. Menopause 2011; 18: 366-375
• 22 Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1461-1467
• 23 Pockaj B, Loprinzi MD, Sloan JA. et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest 2004; 22: 515-521
• 24 Pockaj BA, Gallagher JG, Loprinzi CL. et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial No1CC. J Clin Oncol 2006; 24: 2836-2841
• 25 Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). ­Integr Cancer Ther 2007; 6: 104-109
• 26 Rostock M, Fischer J, Mumm A. et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecol Endocrinol 2011; 27: 844-848
• 27 Ruhlen RL, Haubner J, Tracy JK. et al. Black ­cohosh does not exert estrogenic effect on the breast. Nutr Cancer 2007; 59: 269-277
• 28 Scambia G, De Vincenzo R, Ranelletti FO. et al. Antiproliferative effect of Silybin on gynaecological malignancies: synergism with Cisplatin and Doxorubicin. Eur J Cancer 1996; 32A: 877-882
• 29 Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signalling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer 2011; 63: 161-173
• 30 Sharma RA, Gescher AJ, Steward WP. Curcu­min: The story so far. Eur J Cancer 2005; 41: 1955-1968
• 31 Sheu T, Jhan H, Hsieh C. et al. Efficacy of antioxidants as a complementary and alternative medicine (CAM) in combination with the ­chemotherapeutic agent doxorubicin. Integr Cancer Ther 2015; 14: 184-195
• 32 Siviero A, Gallo E, Maggini V. et al. Curcumin, a golden spice with low bioavailability. J Herbal Med 2015; 5: 57-70
• 33 Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: a critical review. Menopause 2010; 17: 426-440
• 34 Tyagi AK, Agarwal C, Chan DC, Agarwal R. ­Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, ­cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB48 cells. ­Oncology Reports 2004; 11: 493-499
• 35 Wuttke W, Jarry H, Becker T. et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy?. Maturitas 2003; 44 (Suppl. 01) S9-S20